Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019

BACKGROUND: First-line immune checkpoint inhibitor (ICI) monotherapy for advanced non–small cell lung cancer (NSCLC) was introduced in Japan in February 2017. Limited information is available since that time regarding health care resource use for NSCLC in Japan, where the hospitalization burden is h...

Descripción completa

Detalles Bibliográficos
Autores principales: Goto, Yasushi, Kawamura, Kodai, Fukuhara, Tatsuro, Namba, Yukiko, Aoe, Keisuke, Shukuya, Takehito, Tsuda, Takeshi, Santorelli, Melissa L., Taniguchi, Kazuko, Kamitani, Tetsu, Irisawa, Masato, Kanda, Kingo, Abe, Machiko, Burke, Thomas, Nokihara, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372154/
https://www.ncbi.nlm.nih.gov/pubmed/37519418
http://dx.doi.org/10.1016/j.curtheres.2023.100712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372154/
https://www.ncbi.nlm.nih.gov/pubmed/37519418
http://dx.doi.org/10.1016/j.curtheres.2023.100712

Ejemplares similares